309 related articles for article (PubMed ID: 28983777)
21. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes - Advances in treatment.
McCullough KB; Patnaik MM
Best Pract Res Clin Haematol; 2020 Jun; 33(2):101130. PubMed ID: 32460984
[TBL] [Abstract][Full Text] [Related]
22. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia.
Mittal P; Saliba RM; Giralt SA; Shahjahan M; Cohen AI; Karandish S; Onida F; Beran M; Champlin RE; de Lima M
Bone Marrow Transplant; 2004 May; 33(10):1005-9. PubMed ID: 15048141
[TBL] [Abstract][Full Text] [Related]
23. Current management of patients with chronic myelomonocytic leukemia.
Alfonso A; Montalban-Bravo G; Garcia-Manero G
Curr Opin Oncol; 2017 Jan; 29(1):79-87. PubMed ID: 27849645
[TBL] [Abstract][Full Text] [Related]
24. Detection of bcr-abl mRNA in single progenitor colonies from patients with chronic myeloid leukemia by PCR: comparison with cytogenetics and PCR from uncultured cells.
Schulze E; Krahl R; Thalmeier K; Helbig W
Exp Hematol; 1995 Dec; 23(14):1649-54. PubMed ID: 8542960
[TBL] [Abstract][Full Text] [Related]
25. Chronic myelomonocytic leukemia: lost in classification?
Bowen DT
Hematol Oncol; 2005 Mar; 23(1):26-33. PubMed ID: 16149105
[TBL] [Abstract][Full Text] [Related]
26. Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells.
Carlo-Stella C; Regazzi E; Andrizzi C; Savoldo B; Garau D; Montefusco E; Vignetti M; Mandelli F; Rizzoli V; Meloni G
Haematologica; 1997; 82(3):291-6. PubMed ID: 9234574
[TBL] [Abstract][Full Text] [Related]
27. Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview.
Kuendgen A; Kasprzak A; Germing U
Front Oncol; 2021; 11():778741. PubMed ID: 34869027
[TBL] [Abstract][Full Text] [Related]
28. Diagnosing myelodysplastic/myeloproliferative neoplasms: laboratory testing strategies to exclude other disorders.
Hall J; Foucar K
Int J Lab Hematol; 2010 Dec; 32(6 Pt 2):559-71. PubMed ID: 20670271
[TBL] [Abstract][Full Text] [Related]
29. Approaching First-Line Treatment in Patients With Advanced CMML: Hypomethylating Agents or Cytotoxic Treatment?
Liapis K; Kotsianidis I
Front Oncol; 2021; 11():801524. PubMed ID: 34966690
[TBL] [Abstract][Full Text] [Related]
30. [Clinical features of a new category, myelodysplastic/myeloproliferative diseases, defined by WHO classification].
Fukuhara T; Kakinoki Y
Rinsho Byori; 2006 Mar; 54(3):243-9. PubMed ID: 16637572
[TBL] [Abstract][Full Text] [Related]
31. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.
Padron E; Steensma DP
Curr Opin Hematol; 2015 Mar; 22(2):163-70. PubMed ID: 25575034
[TBL] [Abstract][Full Text] [Related]
32. Making sense of the myelodysplastic/myeloproliferative neoplasms overlap syndromes.
Tiu RV; Sekeres MA
Curr Opin Hematol; 2014 Mar; 21(2):131-40. PubMed ID: 24378705
[TBL] [Abstract][Full Text] [Related]
33. [Chronic myeloid leukemia--treatment].
Stoetzer OJ; Hentrich M; Salat C
Dtsch Med Wochenschr; 2002 Dec; 127(49):2621-4. PubMed ID: 12469275
[No Abstract] [Full Text] [Related]
34. Suboptimal response rates to hypomethylating agent therapy in chronic myelomonocytic leukemia; a single institutional study of 121 patients.
Coston T; Pophali P; Vallapureddy R; Lasho TL; Finke CM; Ketterling RP; Carr R; Binder M; Mangaonkar AA; Gangat N; Al-Kali A; Litzow M; Zblewski D; Pardanani A; Tefferi A; Patnaik MM
Am J Hematol; 2019 Jul; 94(7):767-779. PubMed ID: 30964202
[TBL] [Abstract][Full Text] [Related]
35. A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Bazinet A; Darbaniyan F; Kadia TM; Venugopal S; Kanagal-Shamanna R; DiNardo CD; Borthakur G; Jabbour EJ; Daver NG; Pemmaraju N; Konopleva MY; Ravandi F; Sasaki K; Chien KS; Hammond D; Pierce SA; Kantarjian HM; Garcia-Manero G; Montalban-Bravo G
Cancer; 2023 Feb; 129(4):560-568. PubMed ID: 36458426
[TBL] [Abstract][Full Text] [Related]
36. Chronic Myelomonocytic Leukemia: a Genetic and Clinical Update.
McCullough KB; Patnaik MM
Curr Hematol Malig Rep; 2015 Sep; 10(3):292-302. PubMed ID: 26122388
[TBL] [Abstract][Full Text] [Related]
37. The use of medical claims to assess incidence, diagnostic procedures and initial treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia in the Netherlands.
Dinmohamed AG; van Norden Y; Visser O; Posthuma EF; Huijgens PC; Sonneveld P; van de Loosdrecht AA; Jongen-Lavrencic M
Leuk Res; 2015 Feb; 39(2):177-82. PubMed ID: 25533930
[TBL] [Abstract][Full Text] [Related]
38. Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features.
Calvo X; Garcia-Gisbert N; Parraga I; Gibert J; Florensa L; Andrade-Campos M; Merchan B; Garcia-Avila S; Montesdeoca S; Fernández-RodrÃguez C; Salido M; Puiggros A; Espinet B; Colomo L; Roman-Bravo D; Bellosillo B; Ferrer A; Arenillas L
Blood Adv; 2020 Oct; 4(20):5285-5296. PubMed ID: 33108455
[TBL] [Abstract][Full Text] [Related]
39. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.
Parikh SA; Tefferi A
Am J Hematol; 2012 Jun; 87(6):610-9. PubMed ID: 22615103
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic Hematopoietic Stem Cell Transplantation for Mixed or Overlap Myelodysplastic/Myeloproliferative Disorders.
Symeonidis A; Chondropoulos S; Verigou E; Lazaris V; Kourakli A; Tsirigotis P
Front Oncol; 2022; 12():884723. PubMed ID: 35992818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
